Foresite Capital Management VI’s Celldex Therapeutics CLDX Stock Holding History
Bought
Maintained
Sold
Other funds holding CLDX
KCM
BBA
Foresite Capital Management VI's CLDX Position: Q3 2026 in Review
Foresite Capital Management VI sold out of Celldex Therapeutics (CLDX) in Q3 2026, closing a stake of 879,713 shares — an estimated $32.7M sold.
Foresite Capital Management VI first reported a position in CLDX in Q1 2026 and held it in 2 quarters. The position peaked at $32.7M in Q2 2026. 249 funds tracked by Wall St. Rank hold CLDX as of Q3 2026.
- Foresite Capital Management VI reported no remaining Celldex Therapeutics position as of Q3 2026 after selling out during the quarter.
- Foresite Capital Management VI sold 879,713 Celldex Therapeutics shares in Q3 2026, an estimated $32.7M.
- Foresite Capital Management VI first reported a position in Celldex Therapeutics in Q1 2026 and held it in 2 quarters.
- Foresite Capital Management VI's Celldex Therapeutics position peaked at $32.7M in Q2 2026.
- 249 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q3 2026.
Based on Foresite Capital Management VI's 13F filing for Q3 2026, filed 16 Nov 2026.